Physician profile
Zerline Chambers
NPI 1114012150
$2,208.59
in general payments reported to CMS, 2019-2025
17 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $11.32 · 2021: $282 · 2022: $549 · 2023: $701 · 2024: $193 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.62 |
| Education | $185.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.57 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $431.82 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $306.64 | 2021-2025 | |
| Astellas Pharma US INC | $249.78 | 2022-2024 | Veozah |
| Cardiovascular Systems INC. | $176.00 | 2022 | |
| Minerva Surgical, INC | $154.02 | 2022-2023 | |
| Boston Scientific Corporation | $105.96 | 2019 | |
| Shield Therapeutics INC | $79.79 | 2022-2023 | Accrufer |
| Avion Pharmaceuticals | $69.30 | 2019-2022 | |
| Therapeuticsmd, INC. | $46.80 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $28.61 | 2019-2020 | |
| Lumenis, INC | $23.79 | 2021 | |
| Exeltis, USA INC. | $23.50 | 2023 | Slynd |
| Organon LLC | $22.96 | 2024 | |
| Mylan Pharmaceuticals INC. | $20.10 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.51 | 2019 | |
| Dysis Medical, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zerline Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.